{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:07:16Z","timestamp":1789729636916,"version":"4.0.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antibody-drug conjugates (ADCs) have established targeted payload delivery as an important anticancer strategy, but their efficacy remains constrained by antigen heterogeneity, incomplete internalisation, resistance and dose-limiting toxicity. Bispecific antibody-drug conjugates (BsADCs) add a second antigen- or epitope-binding specificity with the aim of broadening tumour coverage or altering receptor trafficking. The field crossed a major translational threshold in 2026, when izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR\u00d7HER3 BsADC, received its first regulatory approvals in China for previously treated recurrent or metastatic nasopharyngeal carcinoma and oesophageal squamous cell carcinoma, while phase III studies also showed survival benefit in triple-negative breast cancer. These developments shift the central question from whether bispecificity can produce antitumour activity to when it can generate a clinically meaningful therapeutic window. This review evaluates BsADC development through six linked determinants: target-pair biology and co-expression, binding geometry and avidity, internalisation and lysosomal trafficking, linker-payload chemistry and drug-to-antibody ratio, intratumoural distribution and bystander activity, and biomarker-guided dosing and patient selection. We further examine how payload-mediated immunogenic cell death, Fc\/Fc\u03b3 receptor-dependent uptake, suppressive tumour-immune niches and checkpoint-based combinations may modify activity beyond target recognition. Clinical programmes illustrate divergent outcomes: iza-bren provides regulatory validation of the modality, whereas experience with MEDI4276, zanidatamab zovodotin and REGN5093-M114 shows that enhanced binding or internalisation does not guarantee sustainable development. Importantly, much of the mechanistic and combination evidence for immune activation still derives from monospecific ADCs; immune benefit should therefore not be attributed to bispecificity itself without direct evidence. Future progress should integrate human pharmacokinetic\/pharmacodynamic data, target-pair and immune-contexture biomarkers, dose-exposure-toxicity relationships and comparative value over optimized monospecific ADCs.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1974912","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:52:49Z","timestamp":1789728769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[{"name":"General Surgery Centre, First Hospital of Jilin University","place":["Changchun, Jilin, China"]},{"name":"School of Nursing, Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[{"name":"School of Nursing, Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qiang","family":"San","sequence":"additional","affiliation":[{"name":"School of Nursing, Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-feng","family":"Ye","sequence":"additional","affiliation":[{"name":"General Surgery Centre, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: A dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11684-024-1072-8","article-title":"Unlocking the potential of bispecific ADCs for targeted cancer therapy","volume":"18","author":"Zeng","year":"2024","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","article-title":"SystImmune announces first approval of iza-bren for the treatment of recurrent or metastatic nasopharyngeal carcinoma in China","year":"2026"},{"key":"B9","article-title":"SystImmune announces second approval of iza-bren in China for the treatment of recurrent or metastatic esophageal squamous cell carcinoma","year":"2026"},{"key":"B10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12272-026-01595-z","article-title":"Bispecific antibody-drug conjugates: A modular blueprint for next-generation cancer therapeutics","volume":"49","author":"Bai","year":"2026","journal-title":"Arch Pharmacal Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03792-7","article-title":"A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: A phase 1b trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"Abstract 6190","DOI":"10.1158\/1538-7445.Am2024-6190","article-title":"Patterns of EGFR and HER3 co-expression in solid tumors","volume":"84","author":"Wood","year":"2024","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-21-0009","article-title":"A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade","volume":"20","author":"DaSilva","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0014","article-title":"First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1039\/d5cb00096c","article-title":"A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy","volume":"6","author":"Xue","year":"2025","journal-title":"RSC Chem Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaf010","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antibody Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-2180","article-title":"Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC","volume":"29","author":"Oh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"Janne","year":"2022","journal-title":"Cancer Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Nakayama Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2514050","article-title":"Patritumab deruxtecan induces immunogenic cell death","volume":"14","author":"Forveille","year":"2025","journal-title":"OncoImmunology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates","volume":"39","author":"Aoyama","year":"2022","journal-title":"Pharm Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01954-3","article-title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 study in China","volume":"406","author":"Yang","year":"2025","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.4008","article-title":"Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study","volume":"44","author":"Lu","year":"2026","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1003","article-title":"Izalontamab brengitecan (iza-bren) versus physician\u2019s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study","volume":"44","author":"Wu","year":"2026","journal-title":"J Clin Oncol"},{"key":"B40","article-title":"Izalontamab brengitecan (EGFRxHER3 ADC) granted Breakthrough Therapy Designation by U.S. FDA for patients with previously treated advanced EGFR-mutated non-small cell lung cancer","year":"2025"},{"key":"B41","unstructured":"SystImmune and Bristol Myers Squibb announce a global strategic collaboration agreement for the development and commercialization of BL-B01D1\n          \n          \n          \n          2023"},{"key":"B42","unstructured":"A study comparing BL-B01D1 with physician's choice of chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (PANKU-NPC01)\n          \n          \n          \n          2026"},{"key":"B43","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO-25-01929","article-title":"Izalontamab brengitecan in locally advanced or metastatic non-small cell lung cancer with actionable genomic alterations outside of classical EGFR mutations: A Phase Ib study","volume":"44","author":"Zhou","year":"2026","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00243","article-title":"Izalontamab brengitecan (iza-bren), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate in extensive-stage small cell lung cancer: Results from a Phase Ib study","author":"Zhao","year":"2026","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00109","article-title":"Efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic urothelial carcinoma: A Phase II clinical trial","volume":"43","author":"Bian","year":"2025","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.1123","article-title":"JSKN016, a first-in-class anti-TROP2\/HER3 bispecific antibody-drug conjugate (ADC), in patients with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study","volume":"44","author":"Yao","year":"2026","journal-title":"J Clin Oncol"},{"key":"B47","article-title":"JSKN003 pipeline and registrational development update","year":"2026"},{"key":"B48","article-title":"A study to assess change in disease activity and adverse events in adult participants with gynecologic cancers receiving IMGN151 (NCT07024784)","year":"2026"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.8530","article-title":"First-in-human study of DM005, an anti-EGFR\/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors","volume":"44","author":"Yang","year":"2026","journal-title":"J Clin Oncol"},{"key":"B50","article-title":"First in human study of AZD9592 in solid tumors - EGRET (NCT05647122)","year":"2026"},{"key":"B51","article-title":"Henlius doses first patient with c-MET x EGFR bispecific ADC HLX48","year":"2026"},{"key":"B52","article-title":"Zymeworks provides corporate update and reports second quarter 2024 financial results","year":"2024"},{"key":"B53","article-title":"Study of REGN5093-M114 (METxMET antibody-drug conjugate) in adult patients with MET-overexpressing advanced cancer (NCT04982224)","year":"2025"},{"key":"B54","article-title":"Alphamab Oncology announces the first patient dosed in a Phase I clinical study of EGFR\/HER3 dual payload bispecific ADC JSKN021","year":"2026"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: A multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside","volume":"203","author":"Fu","year":"2024","journal-title":"Pharmacol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-25-0108","article-title":"Targeted delivery of a potent STING agonist payload via an antibody-drug conjugate drives robust antitumor activity in preclinical models","volume":"25","author":"Gruber","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1974912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:52:52Z","timestamp":1789728772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1974912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2026.1974912"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1974912","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1974912"}}